This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The 5 Dumbest Things on Wall Street This Week: Oct. 18

5. Coronado's Collapse

You know the old Wall Street adage, right? Bulls make money, bears make money and biotechs selling pig parasite eggs get slaughtered.

OK, OK. Maybe that's not the exact phrasing, but it certainly comes pretty close to describing what happened to Coronado BioSciences' (CNDO) stock this week.

Shares of Coronado tumbled 67% to $1.91 Monday after the company announced that its experimental Crohn's Disease treatment failed an important Phase II study. Coronado's drug, which is referred to as CNDO-21, contains the live eggs of a parasite found in the excrement of pigs (also known as Trichuris suis ova, or TSO). When swallowed, the eggs hatch and grow into tiny whipworms which were intended to stimulate a human's immune system and fight off inflammatory auto-immune diseases like Crohn's.

Yes, it's absolutely disgusting to even think about let alone ingest. Nevertheless, you know what they also say: Any pig parasite egg in a storm.

That is, if only Coronado's drug provided shelter from it, which, unfortunately, it doesn't, despite the company's best attempt to spin the sorry results in its favor.

"These results support the potential of TSO to regulate the immune system in patients with Crohn's disease, particularly those with higher level of disease severity," said Coronado CEO Dr. Harlan Weisman. "We look forward to further analyzing the data from TRUST-I, along with the anticipated data from Dr. Falk Pharma's TRUST-II study in Crohn's disease, to identify the most appropriate development path for TSO."

Mixed, mangled and entirely un-kosher metaphors aside, Crohn's symptoms of patients treated with CNDO-021 failed to respond any better than patients treated with a placebo. And as TheStreet's biotech ax Adam Feuerstein alertly points out, blaming negative study results on a higher-than-expected placebo response is typically the "lame excuse" offered when a drug simply doesn't work.

Look. Weisman understands better than anybody the unenviable position he was put in. He's no dummy. However, he still had to offer his disappointed investors some kind of hope even though his so-called "path for TSO" now looks like a dead end.

What else could he do while standing up there with pig parasite egg on his face?

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
C $52.90 0.00%
BBRY $10.38 0.00%
CNDO $3.97 0.00%
JPM $62.60 0.00%
SWK $99.79 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs